

February 23, 2020

Faiz Ahmad

Richard West

SKADDEN, ARPS, SLATE, MEAGHER &amp; FLOM LLP

One Rodney Square

920 North King Street

Wilmington, Delaware 19801

Ron E Meisler

&amp;

Christopher M. Dressel

155 North Wacker Drive

Chicago, Illinois 60606 - 1720

## Objection to Sale Case No. 19-12748 (LSS)

Dear Madam or Sir,

I am writing to object the Sale Order of Melinta Therapeutics Inc., Case No. 19-12748 (LSS).

Melinta Therapeutics, Inc failed to solicit shareholders' vote for the "voluntary bankruptcy proceeding" and failed to disclose material information. No detailed reorganization proposal is ever being provided or disclosed.

Melinta Therapeutics, Inc/Cempra Pharmaceuticals, Inc. is a repetitive offender to violate SEC security laws, omit material information, mislead investors, breach of fiduciary duty, unjust enrichment. There are currently numerous shareholders related active legal claims filed against the company (see September 30, 2019 financial statement Page 21-23 -NOTE 10 – COMMITMENTS AND CONTINGENCIES). And yet the company continues to omit material information, manipulate financial information to defraud investors and the court.

Melinta Therapeutics, Inc awarded below executive/directors 1,345,000 shares in 2019, what will happen with the Company's 2018 Stock Incentive Plan approved for 1,871,028 shares and the already being awarded 1,345,000 shares. Below table shows the awarded shares distribution. How is it be equitable for all executives to retain millions shares under the reorganized company while all other shareholders receive no recovery. Can a legal statement be issued if the company's directors will forgone all awarded Restricted Stock units and there will be no similar replacement stocks or any incentives plan for these directors for the next one or two year as they have obviously failed the company.

Name	Title of Derivative Security	Number of Shares	Date of Earliest Transaction
Lococo Ryan	Melinta Restricted Stock Units	100,000	10/17/2019
Susan Blum	Melinta Restricted Stock Units	25,000	10/17/2019
Sanfilippo Jennifer A	Melinta Restricted Stock Units	120,000	9/5/2019
Johnson John	Melinta Restricted Stock Units	50,000	5/22/2019
Downey Bruce	Melinta Restricted Stock Units	30,000	6/11/2019
Gill David N	Melinta Restricted Stock Units	30,000	6/11/2019
Zaccardelli David	Melinta Restricted Stock Units	30,000	6/11/2019
Ferro Kevin	Melinta Restricted Stock Units	30,000	6/11/2019
Koestler Thomas P	Melinta Restricted Stock Units	30,000	6/11/2019
Galeota James JR.	Melinta Restricted Stock Units	30,000	6/11/2019
Milligan Peter J	Melinta Restricted Stock Units	150,000	6/11/2019
Cammarata Sue.	Melinta Restricted Stock Units	120,000	5/16/2019
Johnson John	Melinta Restricted Stock Units	400,000	2/22/2019
Timothy Simon	Melinta Restricted Stock Units	200,000	5/16/2019
Total		1,345,000	Shares

Melinta Therapeutics, Inc failed to disclose below material information. What happened to below director/owners's stocks? Why there have been no stock sale transactions being reported to SEC that required by Federal Security Law and posted on company website.


Name	Non-Derivative Securities Acquired	Total Number of Shares following the transaction	Date of Transaction
Vatera Healthcare Partners LLC	Common Stock	16,007,237	1/2/2019
VHPM Holdings LLC	Common Stock	600,722	1/2/2019
Johnson John	13,000	37,400	6/27/2019
Johnson John	50,000	50,400	5/22/2019

On October 24, 2019, Melinta Therapeutics, Inc. announced FDA has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia. In addition, Melinta Therapeutics, Inc. have four commercial products, Orbactiv® (oritavancin), Minocin® (minocycline) for Injection, Baxdela® (delafloxacin) and Vabomere® (meropenem and vaborbactam).

On November 12, 2019, Melinta Therapeutics, Inc. released financial statement include Goodwill impairment written off in the amount of \$176,725,000. Goodwill and In-process research and development were recorded at \$17 million and \$19 million respectively as of September 30, 2018 financial statements. In December 31, 2018, the company conducted a goodwill impairment test to bring it to reflect market capitalization value and wrote off Goodwill impairment in the amount of \$25,088,000. After this goodwill written off, both Goodwill and In-process research and development accounts were depleted to zero as of December 31, 2018.

What was the justifications to reduce Intangible assets by \$176,725,000 and bring down the Intangible Assets from \$229 million in December 31, 2018 to \$40 million in September 30, 2019 financial statement?


Melinta Therapeutics, Inc. Intangible assets include four FDA approved commercial products plus recent approved BAXDELA. The average useful life for Intangible assets are between 13 to 17 years. The company also own two pipeline phase 2 clinical trial projects. In September 30, 2019 financial statement, the company wildly projected cash flow for the next 13-17 years with discounted rate at 22.6% APR, and arrived an outrageous number to reduce 99.98% of Intangible assets just to get court to approve for chapter 11 reorganization.






Melinta Therapeutics, Inc's revenue have steadily gone up from \$12 million in second quarter 2018 to \$15.8 million in third quarter 2019 except in December 31, 2018 and September 30, 2018 quarters, the revenues were \$35 million and \$34 million respectively.

Another interesting observation is that Melinta Therapeutics, Inc. prepaid vendors by almost double amount \$9.5 million in September 30, 2019 quarter comparing with \$5.2 million in previous quarter, and the average prepaid expenses in all past quarters are \$5.6 million for the company. Likely, the company was trying to reduce cash balance in order to appear to be more insolvent for the court proceedings. The company has cash and cash equivalent balance of \$63.5 million as of September 30, 2019 financial statement.



Lastly, Melinta Therapeutics Inc. is not delinquent in any payment due to Deerfield Management Company, L.P., / ("Credit Facility") and the principal of the Term Loan must be paid by January 5, 2024 which is 3 years away. Further, the Credit Facility do not allow for prepayment until January 2021, and prepayment penalties equal to 2%. Melinta Therapeutics Inc. has been operated under going concern since December 2017 prior the loan agreement and all through present. Deerfield Management Company amended the loan agreement in January 2019 to require year ending December 31, 2019 financial statement with an audit opinion without a going concern qualification reflects excessive demand or ill intention. Deerfield Management Company, L.P has been compensated by charging 11.75% - 14.75% APR for interest rate for up to \$240 million loan, currently only \$89 million of the \$240 million loan was drawn by Melinta Therapeutics Inc. And yet, Deerfield Management Company, L.P want to acquire full ownership of its borrower for additional \$51 million after the company's new drug approval and force out existing shareholders with no recovery.

The voluntary bankruptcy proceeding was filed without shareholders' votes and agreed upon, and certainly financial information were grossly manipulated and misleading. Melinta Therapeutics Inc. offers top of the line products and recently has new drug approval and its commercial launch being intentionally delayed to hurt existing shareholders. An "expedited" bankruptcy process with no recovery or no equitable compensation to shareholders is gravely unjust, it serves for similar predatory practices engaged by the companies, which created so many legal complaints. This voluntary bankruptcy proceeding provide no time for the company to search for a better tender offer, and only aids in Deerfield Management Company, L.P and Melinta Therapeutics Inc. executives' efforts to defraud shareholders while they capture all future benefits.

  
Lin Luo

	Three Months Ended September 30,	
	2019	2018
Warrants outstanding	766,680	770,486
Stock options outstanding	535,474	397,429
Restricted stock units outstanding	1,305,500	56,092
	2,607,654	1,224,007

**NOTE 10 – COMMITMENTS AND CONTINGENCIES**

As discussed in Note 11, on November 3, 2017, Melinta merged with Cempra, Inc. in a business combination. Prior to the merger, on November 4, 2016, a securities class action lawsuit was commenced in the United States District Court, Middle District of North Carolina, Durham Division, naming Cempra, Inc. (now known as Melinta Therapeutics, Inc.) (for purposes of this Contingencies section, “Cempra”) and certain of Cempra’s officers as defendants. Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016, and December 30, 2016, respectively. Pursuant to the Private Securities Litigation Reform Act, on July 6, 2017, the court consolidated the three lawsuits into a single action and appointed a lead plaintiff and co-lead counsel in the consolidated case. On August 16, 2017, the plaintiff filed a consolidated amended complaint. The plaintiff alleged violations of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with allegedly false and misleading statements made by the defendants between July 7, 2015, and November 4, 2016 (the “Class Period”). The plaintiff sought to represent a class comprised of purchasers of Cempra’s common stock during the Class Period and sought damages, costs and expenses and such other relief as determined by the court. On September 29, 2017, the defendants filed a motion to dismiss the consolidated amended complaint. After the motion to dismiss was fully briefed, the court heard oral arguments on July 24, 2018. On October 26, 2018, the court granted the defendants’ motion to dismiss and dismissed the plaintiff’s consolidated amended complaint in its entirety. On November 21, 2018, the plaintiff filed its notice of appeal, and on December 20, 2018, the Fourth Circuit entered its briefing schedule. The appellant filed its brief on January 28, 2019; the appellee filed its response brief on February 27, 2019; and the appellant filed its reply brief on March 20, 2019. The court has not yet ruled on the appeal. We believe that we have meritorious defenses and intend to defend the lawsuit vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On December 21, 2016, a shareholder derivative lawsuit was commenced in the North Carolina Durham County Superior Court, naming certain of Cempra’s former and current officers and directors as defendants and Cempra as a nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and corporate waste (the “December 2016 Action”). A substantially similar lawsuit was filed in the North Carolina Durham County Superior Court on February 16, 2017 (the “February 2017 Action”). The complaints are based on similar allegations as asserted in the securities lawsuits described above and seek unspecified damages and attorneys’ fees. Both cases were served and transferred to the North Carolina Business Court as mandatory complex business cases. The Business Court consolidated the February 2017 Action into the December 2016 Action and appointed counsel for the plaintiff in the December 2016 Action as lead counsel. On July 6, 2017, the court stayed the action pending resolution of the putative securities class action. That stay was then lifted. The plaintiff filed an amended complaint on December 29, 2017, and was required to file a further amended complaint by February 6, 2018. On February 6, 2018, the plaintiff filed his second amended complaint. On March 8, 2018, the defendants filed their motion to dismiss or, in the alternative, stay the plaintiff’s second amended complaint. On April 9, 2018, the plaintiff filed his opposition to the defendants’ motion. The defendants filed their reply on April 26, 2018. On June 27, 2018, the parties filed a joint stipulation and consent order to stay the case until (1) 30 days after a final order dismissing the putative securities class action with prejudice is entered; or (2) the parties file a joint stipulation to terminate the stay in the event that a plaintiff in a subsequently filed derivative action makes similar allegations and does not agree to stay the proceedings on substantially the same terms. On June 29, 2018, the court entered an order staying the case pursuant to the joint stipulation, which expired by its term following entry of the court’s dismissal order in the above putative securities class action. On November 29, 2018, the parties filed a second joint stipulation to continue the stay until (1) 30 days after the putative securities class action appeal and any appeals therefrom have been resolved; or (2) the parties file a joint stipulation to terminate the stay in the event that a plaintiff in a subsequently filed derivative action makes similar allegations and does not agree to a stay of proceedings on substantially the same terms. On November 30, 2018, the court entered an order staying the case pursuant to the second joint stipulation. We believe that we have meritorious defenses and we intend to defend the lawsuit vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On January 3, 2018, the plaintiff who commenced the February 2017 Action, which was subsequently consolidated into the December 2016 Action, transmitted to the former Acting Chief Executive Officer of Cempra a litigation demand (the “Demand”). The Demand requested that Cempra’s Board of Directors (the “Board”) “commence an independent investigation into the matters raised” in the complaint filed in the February 2017 Action and the Demand, “take any and all appropriate steps



for Cemptra to recover, through litigation if necessary, the damages proximately caused by the directors' and officers' alleged breaches of fiduciary duty," and "implement corporate governance enhancements to prevent recurrence of the alleged wrongdoing." The Board has not yet formally responded to the Demand.

On July 31, 2017, a shareholder derivative lawsuit was commenced in the Court of Chancery of the State of Delaware, naming certain of Cemptra's former and current officers and directors as defendants and Cemptra as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, and corporate waste. The complaint is based on similar allegations as asserted in the putative securities class action described above and seeks unspecified damages and attorneys' fees. On October 23, 2017, the defendants filed a motion to dismiss or, in the alternative, stay, the complaint, which was supported by an opening brief filed on November 9, 2017. On January 8, 2018, the plaintiff filed his answering brief in opposition to the defendants' motion. The defendants filed their reply in support of their motion on February 7, 2018. On June 18, 2018, the parties filed a joint letter (1) indicating they have agreed to stay the case until the pending motion to dismiss in the November 4, 2016, consolidated federal securities action pending in the United States District Court, Middle District of North Carolina, Durham Division is decided; and (2) requesting that the June 22, 2018, oral argument scheduled for the defendants' motion to dismiss be canceled. On June 27, 2018, the parties filed a stipulation and proposed order to stay the case until (1) 30 days after a final order dismissing the November 4, 2016, consolidated federal securities action pending in the United States District Court, Middle District of North Carolina, Durham Division with prejudice is entered; or (2) the parties file a joint stipulation to terminate the stay in the event that a plaintiff in a subsequently filed derivative action makes similar allegations and does not agree to stay the proceedings on substantially the same terms. On June 28, 2018, the court granted the proposed order and stayed the case on such terms, with that stay expiring by its term following entry of the court's dismissal order in the above putative securities class action. On November 28, 2018, the parties filed a joint stipulation agreeing to stay the case, including all discovery, until (1) 30 days after the appeal for the November 4, 2016, consolidated federal securities action pending in the United States District Court, Middle District of North Carolina, Durham Division, and any appeals therefrom, was resolved or (2) the parties file a joint stipulation to terminate the stay in the event that a plaintiff in a subsequently filed derivative action makes similar allegations and does not agree to a stay of proceedings on substantially the same terms. On November 30, 2018, the court stayed the case pursuant to the joint stipulation. We believe that we have meritorious defenses and we intend to defend the lawsuit vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On September 15, 2017, a shareholder derivative lawsuit was commenced in the United States District Court for the Middle District of North Carolina, Durham Division, naming certain of Cemptra's former and current officers and directors as defendants and Cemptra as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and violation of Section 14(a) of the Exchange Act. The complaint is based on similar allegations as asserted in the putative securities class action described above and seeks unspecified damages and attorneys' fees. On December 1, 2017, the parties filed a joint motion seeking to stay the shareholder derivative lawsuit pending resolution of the putative securities class action, which stipulation was ordered by the court on December 11, 2017. We believe that we have meritorious defenses and we intend to defend the lawsuit vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants.

On October 22, 2018, the Company received a litigation demand on behalf of putative Cemptra shareholder Dr. Alan Cauldwell (the "Demand"), purporting to reinstate Dr. Cauldwell's previous demand, dated as of January 3, 2018, held in abeyance after further discussion and negotiation with the Company. The Demand appears premised on the same factual allegations as the shareholder derivative lawsuits previously filed against the Company, as detailed above, and requests, in part, that Cemptra's board of directors commence an investigation of the misconduct alleged therein. On November 1, 2019, the Company, certain former officers and directors, and Dr. Cauldwell entered into a tolling agreement with respect to the claims asserted in the Demand. We believe that we have meritorious defenses to Dr. Cauldwell's claims, and we intend to defend any litigation relating to the Demand vigorously.

On December 3, 2018, James Naples, a purported Company shareholder, filed a putative class action suit against the Company and its Board of Directors in the Court of Chancery of the State of Delaware, alleging that the Board had breached its fiduciary duties related to a proposed, and subsequently abandoned, \$75,000 common stock financing that was contemplated with affiliates of Vatera Holdings LLC. The suit alleged that the Board of Directors breached its fiduciary duties by, among other things, failing to disclose all material information to Company shareholders. The suit sought, among other things, to enjoin the shareholder vote on the financing proposal until additional disclosures were issued. On February 27, 2019, the suit was voluntarily dismissed with prejudice as moot, though the court retained jurisdiction solely for the purpose of adjudicating a claim by the plaintiff for attorneys' fees and expenses. The Company subsequently agreed to pay \$350 to plaintiff's counsel for attorneys' fees and expenses in full satisfaction of the claim for attorneys' fees and expenses in the Action. The Court has not been asked to review, and will pass no judgment on, the payment of the attorneys' fees and expenses or their reasonableness. The Court closed the matter on June 6, 2019.

On December 18, 2018, we filed a complaint in the Court of Chancery of the State of Delaware against Medicines for breach of contract claim and fraud arising from the Purchase and Sale Agreement ("Purchase Agreement"), dated November 28, 2017, pursuant to which we acquired the IDB from Medicines (the "Medicines Action"). In the complaint, we alleged claims for damages of at least \$68,300. On December 28, 2018, we received a letter from Medicines demanding the payment of Milestone No. 4 under the Agreement and Plan of Merger, dated as of December 3, 2013, among Medicines, Rempex Pharmaceuticals, Inc. and the other parties thereto ("Merger Agreement"), in the amount of \$30,000 (a milestone which the Company had assumed as an "Assumed Liability" under the Purchase Agreement). On January 7, 2019, we notified Medicines that we would not be making the Milestone No. 4 payment in the amount of \$30,000, or the First Deferred Payment in the amount of \$25,000 under the Purchase Agreement, because the Company had asserted claims in the litigation in excess of these amounts. On January 9, 2019, Medicines filed a motion to dismiss our claims, and on March 15, 2019, Medicines filed its Opening Brief in Support of Its Motion to Dismiss. On April 23, 2019, we filed an Amended Complaint alleging claims for damages of at least \$80,000. On May 3, 2019, Medicines filed a motion to dismiss our claims in the Amended Complaint. On June 10, 2019, Medicines filed its brief in support of its motion to dismiss. Our answering brief was filed August 2, 2019, and Medicines' reply brief was filed September 6, 2019. The Court was scheduled to hear oral argument on Medicines' motion on September 19, 2019; however, that hearing was removed from the Court's calendar. The Court has not scheduled a new hearing date.

On March 28, 2019, Fortis Advisors LLC, in its capacity as the authorized legal representative of the former shareholders of Rempex Pharmaceuticals, Inc. ("Former Rempex Shareholders"), filed a complaint in the Court of Chancery of the State of Delaware against Medicines and us (the "Fortis Action"). The Former Rempex Shareholders' complaint alleges breach of contract claims against Medicines arising out of the Merger Agreement and alleges a third-party beneficiary claim against us for breach of the Purchase Agreement. The Former Rempex Shareholders' complaint seeks to hold us and Medicines jointly and severally liable for alleged damages of at least \$30,000, as well as pre- and post-judgment interest, fees, costs, expenses, and disbursements. On April 18, 2019, we filed a motion to dismiss the Former Rempex Shareholders' claim against us. That motion is fully briefed as of July 25, 2019, and the Court heard oral argument on September 19, 2019. Also on April 18, 2019, Medicines filed its answer to the Former Rempex Shareholders' complaint, as well as a crossclaim against us. On June 21, 2019, Medicines filed a Motion for Judgment on the Pleadings in connection with Count I of its crossclaim and its opening brief in support of that motion. Our answering brief was filed August 7, 2019, and Medicines' reply brief was filed September 11, 2019. The Court heard oral argument on that motion, along with our motion to dismiss the Fortis Action. We filed a motion to consolidate the Fortis Action and the Medicines Action on May 8, 2019, and the Court heard oral argument on that motion on July 8, 2019. No ruling has been issued. We believe that we have meritorious defenses and we intend to defend the lawsuit and crossclaim vigorously.

On September 26, 2019, The Scripps Research Institute filed a lawsuit in the United States District Court for the Southern District of California against Castle Acquisition Corp., Cembra Pharmaceuticals, Inc., Cembra, Inc., Melinta Subsidiary Corp., and Melinta Therapeutics, Inc. The complaint asserts causes of action for breach of contract, quasi contract, and unjust enrichment, and seeks payments related to certain agreements. The lawsuit is at an early stage and we are evaluating the claims asserted and potentially available defenses.

Other than as described above, we are not a party to any legal proceedings and we are not aware of any claims or actions pending or threatened against us. In the future, we might from time to time become involved in litigation relating to claims arising from our ordinary course of business.

#### NOTE 11 – SEVERANCE AND EXIT COSTS

A summary of merger and non-merger activity in our severance accrual (included in accrued expenses or long-term liabilities on the condensed consolidated balance sheets) is below.

<b>Balance - December 31, 2018</b>	\$	9,767
Additional severance accruals (recorded in SG&A)		1,024
Severance payments		(9,541)
<b>Balance - September 30, 2019</b>	<u>\$</u>	<u>1,250</u>

On September 30, 2019, all of the balance was included in accrued expenses. We also recognized \$0 and \$218 of additional stock-based compensation expense related to the acceleration of equity awards for terminated employees under ASC 718, *Compensation-Stock Compensation*, as severance expense during the three and nine months ended September 30, 2018. No equity awards were accelerated in 2019.

In March 2019, we terminated our operating lease for our principal research facility in New Haven, Connecticut. In connection with the termination, we agreed to pay the lessor a \$462 early termination fee. As a result, we reduced the lease liability equal to the termination fee and recorded a gain of \$792, which was recorded in other income (expense).



**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation**

*The unaudited interim financial statements and this Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2017, and the related Management's Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2017. As further described in "Note 3 – Merger with Cempira" in our audited financial statements in the Form 10-K, the former private company Melinta was determined to be the accounting acquirer in our November 2017 reverse merger with Cempira and, accordingly, historical financial information for the first quarter of 2017 presented in this Form 10-Q reflects the standalone former private company Melinta and, therefore, period-over-period comparisons may not be meaningful. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to risks and uncertainties, including those set forth under "Part I. Item 1. Business - Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2017, and elsewhere in this report, that could cause actual results to differ materially from historical results or anticipated results.*

**Overview**

We are a commercial-stage pharmaceutical company focused on discovering, developing and commercializing differentiated anti-infectives for the acute care and select community settings to meet critical medical needs in the treatment of bacterial infectious diseases.

We have four commercial products, (i) delafloxacin, distributed under the brand name Baxdela™, (ii) meropenem and vaborbactam as the active pharmaceutical ingredient and distributed under the brand name Vabomere™ ("Vabomere"), (iii) oritavancin as the active pharmaceutical ingredient and distributed under the brand name Orbactiv® ("Orbactiv") and (iv) minocycline as the active pharmaceutical ingredient and distributed under the brand name Minocin® for injection ("Minocin") and line extensions of such products. Melinta is also investigating Baxdela as a treatment for community acquired bacterial pneumonia ("CABP"). We also have a proprietary drug discovery platform, enabling a unique understanding of how antibiotics combat infection, and have generated a pipeline spanning multiple phases of research and clinical development. The formal commercial launch of Baxdela occurred in February 2018.

The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern. We are not currently generating revenue from operations that is significant relative to its level of operating expenses and do not anticipate generating revenue sufficient to offset operating costs in the short-term to mid-term. We have financed our operations to date principally through the sale of equity securities, debt financing and licensing and collaboration arrangements.

We have incurred losses from operations since our inception and had an accumulated deficit of \$592.1 million as of March 31, 2018. We expect to incur substantial expenses and further losses in the foreseeable future for the research, development, and commercialization of our product candidates and approved products. As a result, we will need to fund our operations through public or private equity offerings, debt financings, or corporate collaborations and licensing arrangements. We have concluded it is not yet probable that our current operating plans, existing cash and cash collections from existing revenue arrangements and product sales will be sufficient to fund our operations for the next twelve months.

Management is currently pursuing various funding options, including seeking additional equity or debt financing and grants, as well as a strategic collaboration or partnership to obtain additional funding or expand its product offerings. While the recent acquisition of IDB from The Medicines Company does provide us with incremental revenues, the cost to further develop and commercialize Baxdela and to support the IDB products is expected to significantly exceed revenues for at least the next twelve months. While there can be no assurance that we will be successful in our efforts, we have a strong history of raising equity financing to fund our development activities. Should we be unable to obtain adequate financing on reasonable terms in the near term, the Company's business, result of operations, liquidity and financial condition would be materially and negatively affected, and we would be unable to continue as a going concern. Additionally, there can be no assurance that, assuming we are able to strengthen our cash position, we will achieve sufficient revenue or profitable operations to continue as a going concern. Our history of operating losses, limited cash resources and lack of certainty regarding obtaining significant financing or timing thereof, raise substantial doubt about our ability to continue as a going concern absent a strengthening of our cash position. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should we be unable to continue as a going concern.

**Recent Developments**

On January 5, 2018, we acquired the IDB from Medicines, including the capital stock of certain subsidiaries of Medicines and certain assets related to its infectious disease business, including Vabomere, Orbactiv and Minocin.

In connection with the acquisition of the IDB, we entered into a new financing agreement, the Facility Agreement, with an affiliate of Deerfield Management Company, L.P. (together with certain funds managed by Deerfield Management Company, L.P.

February 24, 2020

Summary of Claims filed

My name is Lin Luo, born in 1976. I own 19,543 share of Melinta Therapeutics Inc common stocks as of today. Below are some details.

Bank of America Merrill Edge account# IRA-Edge [REDACTED] BH50: 14,158 share of common stocks as of Dec 26, 2019


Acquired 2,575 share on January 13, 2019

Bank of America Merrill Edge account# is CMA-Edge [REDACTED] BN69 - 567 share of common stocks

Bank of America Merrill Edge account# is Roth IRA-Edge [REDACTED] BK93. - 2,234 share of common stocks

I am a new investor and have invested all of my money with Melinta Therapeutics Inc mainly because of the news for the company's new drug application submission and later approval. But the FDA approved new drug was delayed its commercial launch and subsequently filed for this voluntary bankruptcy proceeding instead. When I sold 5000 share of Melinta therapeutic Inc, stock on November 14, 2019, I intended the transactions to be LIFO base in order to show more income or less loss for immigration sponsorship of my family. But the trade platform systems default in FIFO which resulted huge realized loss. Being a new investor, I learned later on how to click the available button to change cost basis from default FIFO to LIFO, which would have helped to reduce less realized loss. I have full control of what cost basis and stock to sell. I provided bank statements for all stocks' purchase price and quality that being acquired. Therefore, please use average cost basis for my claims.

Thank you,



Lin Luo

11510 Bucknell Drive Apt. 204

Silver Spring MD 20902

Email: [lnnluo@hotmail.com](mailto:lnnluo@hotmail.com) Phone# 240-676-5824



**Fill in this information to identify the case:**

Debtor 1 Lin Luo

Debtor 2 \_\_\_\_\_  
(Spouse, if filing)

United States Bankruptcy Court for the: District of Delaware

Case number 19-12748-LSS

**Official Form 410****Proof of Claim**

04/19

**Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.**

**Filers must leave out or redact** information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. **Do not send original documents;** they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

**Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.**

**Part 1: Identify the Claim**

1. Who is the current creditor?	<u>Lin Luo</u> Name of the current creditor (the person or entity to be paid for this claim)  Other names the creditor used with the debtor _____	
2. Has this claim been acquired from someone else?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. From whom? _____	
3. Where should notices and payments to the creditor be sent?  Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	<b>Where should notices to the creditor be sent?</b>  <u>Lin Luo</u> Name <u>11510 Bucknell Drive Apt 204</u> Number Street <u>Silver Spring</u> <u>MD</u> <u>20902</u> City State ZIP Code Contact phone <u>240-676-5824</u> Contact email <u>lnnluo@hotmail.com</u>  Uniform claim identifier for electronic payments in chapter 13 (if you use one): _____	<b>Where should payments to the creditor be sent? (if different)</b>  _____ Name _____ Number Street _____ City State ZIP Code Contact phone _____ Contact email _____
4. Does this claim amend one already filed?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Claim number on court claims registry (if known) _____ Filed on _____ MM / DD / YYYY	
5. Do you know if anyone else has filed a proof of claim for this claim?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Who made the earlier filing? _____	

**Part 2: Give Information About the Claim as of the Date the Case Was Filed**

6. Do you have any number you use to identify the debtor? ☐ No  
☒ Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: 3 H 5 0

7. How much is the claim? \$ 55,924.10 Does this amount include interest or other charges?  
☒ No  
☐ Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).

8. What is the basis of the claim? Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.  
 Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).  
 Limit disclosing information that is entitled to privacy, such as health care information.  
14158 quantity stock share of MLNT @ ave purchase prices of 3.95

9. Is all or part of the claim secured? ☒ No  
☐ Yes. The claim is secured by a lien on property.  
**Nature of property:**  
☐ Real estate. If the claim is secured by the debtor's principal residence, file a *Mortgage Proof of Claim Attachment* (Official Form 410-A) with this *Proof of Claim*.  
☐ Motor vehicle  
☐ Other. Describe: \_\_\_\_\_  
**Basis for perfection:** \_\_\_\_\_  
 Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)  
**Value of property:** \$ \_\_\_\_\_  
**Amount of the claim that is secured:** \$ \_\_\_\_\_  
**Amount of the claim that is unsecured:** \$ \_\_\_\_\_ (The sum of the secured and unsecured amounts should match the amount in line 7.)  
**Amount necessary to cure any default as of the date of the petition:** \$ \_\_\_\_\_  
**Annual Interest Rate** (when case was filed) \_\_\_\_\_ %  
☐ Fixed  
☐ Variable

10. Is this claim based on a lease? ☒ No  
☐ Yes. Amount necessary to cure any default as of the date of the petition. \$ \_\_\_\_\_

11. Is this claim subject to a right of setoff? ☒ No  
☐ Yes. Identify the property: \_\_\_\_\_



## 12. Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?

☒ No☐ Yes. Check one:

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

☐ Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).

Amount entitled to priority

\$ \_\_\_\_\_

☐ Up to \$3,025\* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).

\$ \_\_\_\_\_

☐ Wages, salaries, or commissions (up to \$13,650\*) earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier. 11 U.S.C. § 507(a)(4).

\$ \_\_\_\_\_

☐ Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).

\$ \_\_\_\_\_

☐ Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).

\$ \_\_\_\_\_

☐ Other. Specify subsection of 11 U.S.C. § 507(a)( ) that applies.

\$ \_\_\_\_\_

\* Amounts are subject to adjustment on 4/01/22 and every 3 years after that for cases begun on or after the date of adjustment.

**Part 3: Sign Below**

The person completing this proof of claim must sign and date it. FRBP 9011(b).

If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Check the appropriate box:

☒ I am the creditor.☐ I am the creditor's attorney or authorized agent.☐ I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.☐ I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.


I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgment that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on date 02/12/2020

MM / DD / YYYY



Signature

Print the name of the person who is completing and signing this claim:

Name Lin Luo  
First name Middle name Last name

Title \_\_\_\_\_

Company \_\_\_\_\_

Identify the corporate servicer as the company if the authorized agent is a servicer.

Address 11510 Bucknell Drive Apt 204  
Number Street

Silver Spring MD 20902  
City State ZIP Code

Contact phone 240-676-5824 Email Innluo@hotmail.com

February 12, 2020

Dear Madam or Sir,

My name is Lin Luo, born in 1976, a shareholder of Melinta Therapeutics Inc. Below is a summary of major transactions for my Bank of America Merrill Edge account# IRA-Edge [REDACTED] H50. As of December 26, 2019, I own 14,158 shares of Melinta Therapeutics Inc common stock, with average purchase price of \$3.95, and the total cost was \$55,924.10; I purchased 2,575 share on January 13, 2020 and own 16,733 shares of Melinta Therapeutics Inc as of today, with average purchase price of \$3.95, and the total cost was \$66,095.23.

Settlement Date	Purchase Description	Quantity	Price	Amount
As of 1/13/2020	MELINTA THERAPEUTICS INC	16,733	\$3.95	\$66,095.35
As of 12/26/2019	MELINTA THERAPEUTICS INC	14,158	\$3.95	\$55,924.10
11/19/2019	MELINTA THERAPEUTICS INC	(5,000)	\$1.74	(\$8,700.00)
11/14/2019	MELINTA THERAPEUTICS INC	1,523	\$2.05	\$3,121.10
11/7/2019	MELINTA THERAPEUTICS INC	594	\$2.07	\$1,229.58
11/7/2019	MELINTA THERAPEUTICS INC	1,107	\$2.55	\$2,822.74
11/4/2019	MELINTA THERAPEUTICS INC	583	\$2.64	\$1,539.12
10/29/2019	MELINTA THERAPEUTICS INC	2,828	\$3.60	\$10,180.80
10/25/2019	MELINTA THERAPEUTICS INC	2,742	\$4.74	\$12,997.08
10/22/2019	MELINTA THERAPEUTICS INC	1,812	\$4.28	\$7,762.31
10/14/2019	MELINTA THERAPEUTICS INC	1,341	\$3.78	\$5,075.93
10/11/2019	MELINTA THERAPEUTICS INC	1,345	\$3.85	\$5,185.20
10/3/2019	MELINTA THERAPEUTICS INC	932	\$3.51	\$3,271.32
7/18/2019	MELINTA THERAPEUTICS INC	1,506	\$4.03	\$6,069.18
7/15/2019	MELINTA THERAPEUTICS INC	1,200	\$5.02	\$6,024.00
7/15/2019	MELINTA THERAPEUTICS INC	680	\$4.85	\$3,298.00
7/15/2019	MELINTA THERAPEUTICS INC	658	\$4.70	\$3,092.60
7/15/2019	MELINTA THERAPEUTICS INC	1,251	\$4.62	\$5,779.62
7/12/2019	MELINTA THERAPEUTICS INC	796	\$5.38	\$4,282.48
7/10/2019	MELINTA THERAPEUTICS INC	340	\$6.26	\$2,128.40
Total	MELINTA THERAPEUTICS INC	21,238	\$3.95	\$83,859.46

Sincerely,



Lin Luo

11510 Bucknell Drive Apt. 204

Silver Spring MD 20902

Email: [lnnluo@hotmail.com](mailto:lnnluo@hotmail.com) Phone# 240-676-5824



Online at: [www.merrilledge.com](http://www.merrilledge.com)

Account Number: [REDACTED] 3H50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450MLPF&S CUST FPO  
LIN LUO IRA  
FBO LIN LUO  
11510 BUCKNELL DR APT 204  
SILVER SPRING MD 20902-2801

Net Portfolio Value: \$10,059.95

Your Merrill Office:  
Merrill EDGE  
FL9-802-03-05  
P.O. BOX 40486  
JACKSONVILLE, FL 32203

## RETIREMENT ACCOUNT

This account is enrolled in the Preferred Rewards Platinum tier

October 01, 2019 - December 31, 2019

	This Statement	Year to Date
<b>Opening Value (10/01)</b>	<b>\$34,467.85</b>	
Total Credits	0.21	36,553.57
Total Debits	-	(8,000.00)
Securities You Transferred In/Out	-	-
Market Gains/(Losses)	(24,408.11)	(42,510.13) *
<b>Closing Value (12/31)</b>	<b>\$10,059.95</b>	

### ASSETS

	December 31	September 30
Cash/Money Accounts	1.71	5.90
Fixed Income	-	-
Equities	10,058.24	24,333.90
Mutual Funds	-	10,128.05
Options	-	-
Other/Annuities/Insurance	-	-
Subtotal (Long Portfolio)	10,059.95	34,467.85
<b>TOTAL ASSETS</b>	<b>\$10,059.95</b>	<b>\$34,467.85</b>

### LIABILITIES

Debit Balance	-	-
<b>TOTAL LIABILITIES</b>	<b>-</b>	<b>-</b>
<b>NET PORTFOLIO VALUE</b>	<b>\$10,059.95</b>	<b>\$34,467.85</b>

Merrill Lynch, Pierce, Fenner & Smith Incorporated (also referred to as "MLPF&S" or "Merrill") makes available certain investment products sponsored, managed, distributed or provided by companies that are affiliates of Bank of America Corporation (BofA Corp). MLPF&S is a registered broker-dealer, Member SIPC and a wholly owned subsidiary of BofA Corp.

Investment products: ☐ Are Not FDIC Insured ☐ Are Not Bank Guaranteed ☐ May Lose Value

For best printing results, change page orientation to landscape.

## Account Holdings for IRA-Edge [REDACTED] H50

IRA-Edge [REDACTED] H50

\$6,647.54

+\$129.48 +1.99%

Dow 29,276.34 -0.48 -0.00%

NASDAQ 9,638.94 +10.55

+0.11%

S&amp;P 500 3,357.75 +5.66

+0.17%

10 Year T-Note 1.60 +0.05

+3.84%

Real-time quotes

Group by ☒ Account ☐ Product Class

As of 02/11/2020 06:16 PM ET

Cash available to invest  
\$4.96Settled cash buying power  
\$4.96Unsettled cash  
\$0.00

IRA-Edge [REDACTED] H50

Value  
\$6,647.54Day's Value Change  
+\$129.48 +1.99%Select view 

Symbol	Description	Price	Quantity	\$ Chg	Day's Price % Chg	Day's Value Change \$	Cost Basis	Value	Unrealize \$ Chg
AVGR	AVINGER INC	\$0.6401	10	+\$0.0116	+1.85%	+\$0.11	\$9.80	\$6.40	-\$3.40
BLCM	BELLICUM	03:59 PM ET \$10.16	1	-\$1.19	-10.49%	-\$1.19	\$8.10	\$10.16	+\$2.06
KMPH	KEMPHARM INC SHS	\$0.3511	10	-\$0.0189	-5.11%	-\$0.19	\$4.20	\$3.51	-\$0.69
KTOV	KITOV PHARMA LTD	\$0.7249	10	+\$0.0439	+6.45%	+\$0.44	\$7.32	\$7.25	-\$0.07
MBRX	MOLECULIN BIOTECH INC	\$0.7506	10	-\$0.0044	-0.58%	-\$0.04	\$10.20	\$7.51	-\$2.69
MLNTQ	MELINTA THERAPEUTICS INC	\$0.3110	16,733 *	+\$0.0008	+0.26%	+\$13.38	\$24,475.67	\$5,203.96	-\$19,271.71 *
ONTX	ONCONOVA THERAPEUTICS	\$0.5110	10	-\$0.0890	-14.83%	-\$0.89	\$2.66	\$5.11	+\$2.45
PTN	PALATIN TECHNOLOGIES INC	\$0.6031	10	-\$0.1038	-14.68%	-\$1.04	\$8.10	\$6.03	-\$2.07
SVM	SILVERCORP METALS INC	\$4.14	10	-\$0.09	-2.13%	-\$0.90	\$37.90	\$41.40	+\$3.50
TRXC	TRANSENTERIX INC REG SHS	\$1.22	1,092	+\$0.11	+9.91%	+\$120.12	\$2,099.50	\$1,332.24	-\$767.26
VBIV	VBI VACCINES INC	\$1.57	10	\$0.00	0.00%	\$0.00	\$5.04	\$15.70	+\$10.66
VLRX	VALERITAS HOLDINGS INC	\$0.3312	10	-\$0.0313	-8.63%	-\$0.32	\$12.80	\$3.31	-\$9.49
<b>Balances</b>									
Money accounts	BANK OF AMERICA, NA RASP	\$1.00	4.9600	\$0.00	0.00%	\$0.00	\$4.96	\$4.96	--
Cash balance								\$0.00	
Pending activity								\$0.00	
<b>Total</b>						+\$129.48		\$6,647.54	-\$20,038.71

## Holdings by Product Class Report

The data displayed is for informational purposes only. Your account statement is the official record of your holdings and balances.

Review a description of the third-party ratings methodology.

Please note: None of Bank of America, Merrill Lynch or any affiliates, bears any responsibility or liability with respect to third-party research made available. Clients should understand that they assume full responsibility for any trading decisions they make based upon third-party ratings or reports.

Money accounts are not adjusted for pending trades.

Real-time market data on this page are for informational purposes only. The accuracy of this data is not warranted.

Quotes provided by Nasdaq Basic.

Information will not appear if a cost basis is not known, a security price is not currently available, or the Gain/(Loss) calculations are not appropriate for the type of holding.

Positions are net and cost basis excludes fractional shares.

Total unit cost represents weighted average acquisition price. It does not imply that any shares were actually purchased at that price.

Quotes provided by Nasdaq Basic.





FBO LIN LUO

Account Number: [REDACTED] H50

## YOUR RETIREMENT ACCOUNT ASSETS

October 01, 2019 - December 31, 2019

CASH/MONEY ACCOUNTS	Description	Quantity	Total Cost Basis	Estimated Market Price	Estimated Market Value	Estimated Annual Income	Est. Annual Yield%
CASH		0.02	0.02		.02		.05
+	BANK OF AMERICA, NA RASP	1.69	1.69	1.0000	1.69		
	-FDIC INSURED NOT SIPC COVERED						
	TOTAL		1.71		1.71		

EQUITIES	Description	Symbol	Acquired	Quantity	Unit Cost Basis	Total Cost Basis	Estimated Market Price	Estimated Market Value	Unrealized Gain/(Loss)	Estimated Annual Income
	AVINGER INC	AVGR	11/12/19	10.0000	0.9800	9.80	1.1400	11.40	1.60	
	BELLCUM PHARMACEUTICALS ORD	BLCM	10/18/19	10.0000	0.8100	8.10	1.2900	12.90	4.80	
	ENCANA CORP CURRENT YIELD 1.59%	ECA	10/22/19	1.0000	4.0300	4.03	4.6900	4.69	.66	1
	KEMPHARM INC SHS	KMPH	12/03/19	2,000.0000	0.4199	839.80	0.3793	758.60	(81.20)	
	KITOV PHARMA LTD ADR	KTOV	10/22/19	10.0000	0.7320	7.32	0.7796	7.80	.48	
	MELINTA THERAPEUTICS INC	MLNT	10/25/19	570.0000	3.6000	2,052.00	0.5311	302.73	(1,749.27)	
			10/31/19	583.0000	2.6400	1,539.12	0.5311	309.63	(1,229.49)	
			11/07/19	594.0000	2.0700	1,229.58	0.5311	315.47	(914.11)	
			11/07/19	1,107.0000	2.5499	2,822.74	0.5311	587.93	(2,234.81)	
			11/12/19	1,523.0000	2.0493	3,121.10	0.5311	808.87	(2,312.23)	
			11/13/19	1,274.0000	1.1200	1,426.88	0.5311	676.62	(750.26)	
			11/13/19	3,360.0000	1.2000	4,032.00	0.5311	1,784.50	(2,247.50)	
			11/13/19	1,751.0000	1.1294	1,977.58	0.5311	929.96	(1,047.62)	
			11/18/19	2,268.0000	1.5700	3,560.76	0.5311	1,204.53	(2,356.23)	
			12/26/19	1,128.0000	1.4700	1,658.16	0.5311	599.08	(1,059.08)	
	Subtotal			14,158.0000		23,419.92		7,519.32	(15,900.60)	

+

021



FBO LIN LUO

Account Number: [REDACTED] 3H50

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

June 29, 2019 - September 30, 2019

DIVIDENDS/INTEREST INCOME TRANSACTIONS (continued)		Quantity		Income		Income	
Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
NET TOTAL						.22	204.01
SECURITY TRANSACTIONS							
Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
Purchases							
07/08	MOLEculIN BIOTECH INC SHS CUS NO 60855D101 UNIT PRICE 1.1800	Purchase	1,158.0000	(1,366.44)		(1,366.44)	
07/09	ALTA MESA RESOURCES INC CUS NO 02133L109 UNIT PRICE .1456	Purchase	6,000.0000	(873.60)		(873.60)	
07/09	FLOTEK INDS INC CUS NO 343389102 UNIT PRICE 3.1900	Purchase	1,000.0000	(3,190.00)		(3,190.00)	
07/10	OPKO HEALTH INC CUS NO 68375N103 UNIT PRICE 2.2800	Purchase	1,077.0000	(2,455.56)	(6.95)	(2,462.51)	
07/10	MEDMEN ENTERPRISES INC CUS NO 58507M107 UNIT PRICE 2.5000	Purchase	1,166.0000	(2,915.00)		(2,915.00)	
07/10	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 6.2600	Purchase	340.0000	(2,128.40)	(6.95)	(2,135.35)	
07/10	PALATIN TECHNOLOGIES INC SHS CUS NO 696077403 UNIT PRICE 1.0200	Purchase	1,242.0000	(1,266.84)		(1,266.84)	
07/11	PALATIN TECHNOLOGIES INC SHS CUS NO 696077403 UNIT PRICE .9300	Purchase	988.0000	(918.84)	(6.95)	(925.79)	
07/12	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 5.3800	Purchase	796.0000	(4,282.48)	(6.95)	(4,289.43)	
07/12	SELLAS LIFE SCIENCES GROUP INC CUS NO 81642T100 UNIT PRICE .1440	Purchase	18,424.0000	(2,653.06)	(6.95)	(2,660.01)	
07/12	SELLAS LIFE SCIENCES GROUP INC CUS NO 81642T100 UNIT PRICE .1406	Purchase	6,080.0000	(854.85)	(6.95)	(861.80)	

+

015

5 of 18



FBO LIN LUO

Account Number: [REDACTED] 3H50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

June 29, 2019 - September 30, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
<b>Purchases</b>							
07/12	VBI VACCINES INC CUS NO 91822J103 UNIT PRICE .8706	Purchase	2,000.0000	(1,741.20)	(6.95)	(1,748.15)	
07/15	OPKO HEALTH INC CUS NO 68375N103 UNIT PRICE 2.1500	Purchase	1,664.0000	(3,577.60)	(6.95)	(3,584.55)	
07/15	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 5.0200	Purchase *	1,200.0000	(6,024.00)	(6.95)	(6,030.95)	
07/15	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 4.8500	Purchase *	680.0000	(3,298.00)	(6.95)	(3,304.95)	
07/15	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 4.7000	Purchase *	658.0000	(3,092.60)	(6.95)	(3,099.55)	
07/15	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 4.6200	Purchase *	1,251.0000	(5,779.62)	(6.95)	(5,786.57)	
07/15	SELLAS LIFE SCIENCES GROUP INC CUS NO 81642T100 UNIT PRICE .1330	Purchase	22,388.0000	(2,977.60)	(6.95)	(2,984.55)	
07/16	MEDMEN ENTERPRISES INC CUS NO 58507M107 UNIT PRICE 2.2600	Purchase	1,414.0000	(3,195.64)	(6.95)	(3,202.59)	
07/18	OPKO HEALTH INC CUS NO 68375N103 UNIT PRICE 2.1200	Purchase	1,727.0000	(3,661.24)	(6.95)	(3,668.19)	
07/18	FUELCCELL ENERGY INC CUS NO 35952H601 UNIT PRICE .4000	Purchase	2,500.0000	(1,000.00)	(6.95)	(1,006.95)	
07/18	FLOTEK INDS INC CUS NO 343389102 UNIT PRICE 3.0600	Purchase	1,000.0000	(3,060.00)	(6.95)	(3,066.95)	
07/18	FLOTEK INDS INC CUS NO 343389102 UNIT PRICE 3.0300	Purchase	361.0000	(1,093.83)	(6.95)	(1,100.78)	
07/18	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 4.0300	Purchase *	1,506.0000	(6,069.18)	(6.95)	(6,076.13)	

+

015

6 of 18



FBO LIN LUO

Account Number: [REDACTED] 3H50

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

DIVIDENDS/INTEREST INCOME TRANSACTIONS				Income		Income	
Date	Description	Transaction Type	Quantity			Year To Date	
Tax-Exempt Interest							
10/17	BANK OF AMERICA, NA RASP PAY DATE 10/16/2019 FROM 09-30 THRU 10-16 CUSIP NUM: 55499U915	Interest			.05		
10/31	BANK OF AMERICA, NA RASP 0.01000 DIV/INT REINVEST PAY DATE 10/30/2019 FROM 09-30 THRU 10-30 CUSIP NUM: 55499U915	Interest	.0100				
	BANK OF AMERICA, NA RASP	Income Total			.01		
	Subtotal (Tax-Exempt Interest)				.06		4.44
Tax-Exempt Dividends							
12/18	SILVERCORP METALS INC HOLDING 10.0000 PAY DATE 12/18/2019	* Foreign Dividend			.13		
12/31	ENCANA CORP HOLDING 1.0000 PAY DATE 12/31/2019	* Foreign Dividend			.02		
	Subtotal (Tax-Exempt Dividends)				.15		199.78
	NET TOTAL				.21		204.22

## SECURITY TRANSACTIONS

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
Purchases							
10/04	MOLECULIN BIOTECH INC SHS CUS NO 60855D101 UNIT PRICE 1.0199	Purchase	600.0000	(611.94)		(611.94)	
10/04	ZTE CORP SHS CUS NO 98878Q105 UNIT PRICE 5.2200	Purchase	800.0000	(4,176.00)		(4,176.00)	
10/07	AVINGER INC CUS NO 053734604 UNIT PRICE .7800	Purchase	1,000.0000	(780.00)		(780.00)	
10/07	EQT CORP CUS NO 26884L109 UNIT PRICE 9.1499	Purchase	328.0000	(3,001.17)		(3,001.17)	
10/07	MELINTA THERAPEUTICS INC	Purchase *	932.0000	(3,271.32)		(3,271.32)	

+

021



FBO LIN LUO

Account Number: [REDACTED] BH50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/ Trading Fees	(Debit)/ Credit	Accrued Interest Earned/(Paid)
<b>Purchases</b>							
	CUS NO 58549G209 UNIT PRICE	3.5100 *					
10/08	SAVARA INC	Purchase	946.0000	(872.21)		(872.21)	
	CUS NO 805111101 UNIT PRICE	.9220					
10/09	ALIBABA GROUP HOLDING LT	Purchase	69.0000	(11,568.54)		(11,568.54)	
	CUS NO 01609W102 UNIT PRICE	167.6600					
10/09	SILVERCORP METALS INC	Purchase	417.0000	(1,672.17)		(1,672.17)	
	CUS NO 82835P103 UNIT PRICE	4.0100					
10/10	ALIBABA GROUP HOLDING LT	Purchase	19.0000	(3,101.94)		(3,101.94)	
	CUS NO 01609W102 UNIT PRICE	163.2600					
10/10	KITOV PHARMA LTD	Purchase	1,274.0000	(929.51)		(929.51)	
	ADR CUS NO 49803V107 UNIT PRICE	.7296					
10/11	MEDMEN ENTERPRISES INC	Purchase	1,378.0000	(2,005.04)		(2,005.04)	
	CUS NO 58507M107 UNIT PRICE	1.4550					
10/15	BAIDU INC SPON ADR	Purchase	14.0000	(1,450.40)	(6.95)	(1,457.35)	
	CUS NO 056752108 UNIT PRICE	103.6000					
10/15	OPKO HEALTH INC	Purchase	1,000.0000	(1,990.00)	(6.95)	(1,996.95)	
	CUS NO 68375N103 UNIT PRICE	1.9900					
10/15	AURORA CANNABIS INC	Purchase	512.0000	(1,996.80)	(6.95)	(2,003.75)	
	CUS NO 05156X108 UNIT PRICE	3.9000					
10/15	SIENNA	Purchase	5,066.0000	(1,317.16)	(6.95)	(1,324.11)	
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE	.2600					
10/16	MELINTA THERAPEUTICS INC	Purchase	1,341.0000	(5,068.98)	(6.95)	(5,075.93)	
	CUS NO 58549G209 UNIT PRICE	3.7800 *					
10/16	MELINTA THERAPEUTICS INC	Purchase	1,345.0000	(5,178.25)	(6.95)	(5,185.20)	
	CUS NO 58549G209 UNIT PRICE	3.8500 *					
10/16	AURORA CANNABIS INC	Purchase	1,186.0000	(4,207.24)	(6.95)	(4,214.19)	

+

021

6 of 23



FBO LIN LUO

Account Number: [REDACTED] BH50

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
Purchases							
	CUS NO 05156X108 UNIT PRICE	3.5474					
10/16	AURORA CANNABIS INC	Purchase	489.0000	(1,838.64)	(6.95)	(1,845.59)	
	CUS NO 05156X108 UNIT PRICE	3.7600					
10/16	AURORA CANNABIS INC	Purchase	479.0000	(1,767.51)	(6.95)	(1,774.46)	
	CUS NO 05156X108 UNIT PRICE	3.6900					
10/16	VBI VACCINES INC	Purchase	2,558.0000	(1,281.56)	(6.95)	(1,288.51)	
	CUS NO 91822J103 UNIT PRICE	.5010					
10/18	APHRIA INC SHS	Purchase	1,001.0000	(4,894.89)	(6.95)	(4,901.84)	
	CUS NO 03765K104 UNIT PRICE	4.8900					
10/18	SIENNA	Purchase	5,495.0000	(1,000.09)	(6.95)	(1,007.04)	
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE	.1820					
10/21	ENCANA CORP	Purchase	562.0000	(2,366.02)	(6.95)	(2,372.97)	
	CUS NO 292505104 UNIT PRICE	4.2100					
10/21	SIENNA	Purchase	9,000.0000	(1,359.00)	(6.95)	(1,365.95)	
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE	.1510					
10/22	BELLICUM PHARMACEUTICALS	Purchase	1,849.0000	(1,490.29)	(6.95)	(1,497.24)	
	ORD CUS NO 079481107 UNIT PRICE	.8060					
10/22	ENCANA CORP	Purchase	474.0000	(1,943.40)	(6.95)	(1,950.35)	
	CUS NO 292505104 UNIT PRICE	4.1000					
10/22	MELINTA THERAPEUTICS INC	Purchase	1,812.0000	(7,755.36)	(6.95)	(7,762.31)	
	CUS NO 58549G209 UNIT PRICE	4.2800					
10/22	TRANSENERX INC	Purchase	2,525.0000	(1,068.08)	(6.95)	(1,075.03)	
	CUS NO 89366M201 UNIT PRICE	.4230					
10/23	ENCANA CORP	Purchase	821.0000	(3,300.42)		(3,300.42)	
	CUS NO 292505104 UNIT PRICE	4.0200					
10/23	VALERITAS HOLDINGS INC	Purchase	500.0000	(635.00)		(635.00)	

+

021



FBO LIN LUO

Account Number: [REDACTED] BH50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
Purchases							
	CUS NO 91914N301 UNIT PRICE	1.2700					
10/24	ENCANA CORP	Purchase	450.0000	(1,813.50)		(1,813.50)	
	CUS NO 292505104 UNIT PRICE	4.0300					
10/24	KITOV PHARMA LTD	Purchase	2,000.0000	(1,464.00)		(1,464.00)	
	ADR CUS NO 49803V107 UNIT PRICE	.7320					
10/24	PALATIN TECHNOLOGIES INC	Purchase	1,210.0000	(993.41)		(993.41)	
	SHS CUS NO 696077403 UNIT PRICE	.8210					
10/24	SILVERCORP METALS INC	Purchase	894.0000	(3,388.26)		(3,388.26)	
	CUS NO 82835P103 UNIT PRICE	3.7900					
10/24	SAVARA INC	Purchase	1,770.0000	(1,529.28)		(1,529.28)	
	CUS NO 805111101 UNIT PRICE	.8640					
10/25	OPKO HEALTH INC	Purchase	451.0000	(874.94)		(874.94)	
	CUS NO 68375N103 UNIT PRICE	1.9400					
10/25	OPKO HEALTH INC	Purchase	2,115.0000	(3,929.88)		(3,929.88)	
	CUS NO 68375N103 UNIT PRICE	1.8581					
10/25	MELINTA THERAPEUTICS INC	Purchase	2,742.0000	(12,997.08)		(12,997.08)	
	CUS NO 58549G209 UNIT PRICE	4.7400					
10/25	VALERITAS HOLDINGS INC	Purchase	448.0000	(573.44)		(573.44)	
	CUS NO 91914N301 UNIT PRICE	1.2800					
10/28	OPKO HEALTH INC	Purchase	1,189.0000	(2,138.70)		(2,138.70)	
	CUS NO 68375N103 UNIT PRICE	1.7987					
10/28	OPKO HEALTH INC	Purchase	2,522.0000	(4,161.30)		(4,161.30)	
	CUS NO 68375N103 UNIT PRICE	1.6500					
10/29	MELINTA THERAPEUTICS INC	Purchase	2,828.0000	(10,180.80)		(10,180.80)	
	CUS NO 58549G209 UNIT PRICE	3.6000					
11/04	MELINTA THERAPEUTICS INC	Purchase	583.0000	(1,539.12)		(1,539.12)	

+



FBO LIN LUO

Account Number: [REDACTED] 3H50

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
<b>Purchases</b>							
	CUS NO 58549G209 UNIT PRICE	2.6400 *					
11/06	PALATIN TECHNOLOGIES INC	Purchase	2,469.0000	(1,999.89)		(1,999.89)	
	SHS CUS NO 696077403 UNIT PRICE	.8100					
11/06	SIENNA	Purchase	7,122.0000	(1,274.84)		(1,274.84)	
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE	.1790					
11/12	MELINTA THERAPEUTICS INC	Purchase	1,107.0000	(2,822.74)		(2,822.74)	
	CUS NO 58549G209 UNIT PRICE	2.5499 *					
11/12	MELINTA THERAPEUTICS INC	Purchase	594.0000	(1,229.58)		(1,229.58)	
	CUS NO 58549G209 UNIT PRICE	2.0700 *					
11/14	AVINGER INC	Purchase	1,713.0000	(1,678.74)		(1,678.74)	
	CUS NO 053734604 UNIT PRICE	.9800					
11/14	MELINTA THERAPEUTICS INC	Purchase	1,523.0000	(3,121.10)		(3,121.10)	
	CUS NO 58549G209 UNIT PRICE	2.0493 *					
11/15	MELINTA THERAPEUTICS INC	Purchase	3,360.0000	(4,032.00)		(4,032.00)	
	CUS NO 58549G209 UNIT PRICE	1.2000					
11/15	MELINTA THERAPEUTICS INC	Purchase	1,751.0000	(1,977.58)		(1,977.58)	
	CUS NO 58549G209 UNIT PRICE	1.1294					
11/15	MELINTA THERAPEUTICS INC	Purchase	1,274.0000	(1,426.88)		(1,426.88)	
	CUS NO 58549G209 UNIT PRICE	1.1200					
11/19	ZTE CORP SHS	Purchase	418.0000	(2,299.00)		(2,299.00)	
	CUS NO 98878Q105 UNIT PRICE	5.5000					
11/20	BELLICUM PHARMACEUTICALS	Purchase	3,342.0000	(2,840.70)		(2,840.70)	
	ORD CUS NO 079481107 UNIT PRICE	.8500					
11/20	MELINTA THERAPEUTICS INC	Purchase	2,268.0000	(3,560.76)		(3,560.76)	
	CUS NO 58549G209 UNIT PRICE	1.5700					
11/27	SIENNA	Purchase	13,176.0000	(2,253.10)		(2,253.10)	

+

021

FBO LIN LUO

Account Number: [REDACTED] 3H50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

October 01, 2019 - December 31, 2019

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/Trading Fees	(Debit)/Credit	Accrued Interest Earned/(Paid)
<b>Purchases</b>							
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE .1710						
12/05	KEMPHARM INC SHS	Purchase	2,000.0000	(839.80)		(839.80)	
	CUS NO 488445107 UNIT PRICE .4199						
12/06	TRANSENTERIX INC	Purchase	5,376.0000	(999.94)		(999.94)	
	CUS NO 89366M201 UNIT PRICE .1860						
12/06	YIELD10 BIOSCIENCE INC	Purchase	6,486.0000	(946.96)		(946.96)	
	CUS NO 98585K201 UNIT PRICE .1460						
12/09	THERAPEUTICSMD INC	Purchase	373.0000	(887.74)		(887.74)	
	CUS NO 88338N107 UNIT PRICE 2.3800						
12/12	TRANSENTERIX INC	Purchase	587.0000	(100.38)		(100.38)	
	CUS NO 89366M201 UNIT PRICE .1710						
12/13	SIENNA	Purchase	19,555.0000	(2,815.92)		(2,815.92)	
	BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE .1440						
12/13	TRANSENTERIX INC	Purchase	600.0000	(102.60)		(102.60)	
	CUS NO 89366M201 UNIT PRICE .1710						
12/16	ONCONOVA THERAPEUTICS	Purchase	5,191.0000	(1,380.81)		(1,380.81)	
	INC CUS NO 68232V405 UNIT PRICE .2660						
12/30	MELINTA THERAPEUTICS INC	Purchase	1,128.0000	(1,658.16)		(1,658.16)	
	CUS NO 58549G209 UNIT PRICE 1.4700 *						
	Subtotal (Purchases)			(169,731.86)	(125.10)	(169,856.96)	
<b>Sales</b>							
10/04	MEDMEN ENTERPRISES INC	Sale	-10,000.0000	14,900.00	(.31)	14,899.69	
	CUS NO 58507M107 UNIT PRICE 1.4900						
10/07	MEDMEN ENTERPRISES INC	Sale	-6,690.0000	11,975.10	(.25)	11,974.85	
	CUS NO 58507M107 UNIT PRICE 1.7900						

+

021



FBO LIN LUO

Account Number: 3H50

24-Hour Assistance: (877) 653-4732  
Access Code: 22-519-73450

October 01, 2019 - December 31, 2019

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

## SECURITY TRANSACTIONS (continued)

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/ Trading Fees	(Debit)/ Credit	Accrued Interest Earned/(Paid)
<b>Sales</b>							
11/19	MELINTA THERAPEUTICS INC CUS NO 58549G209 UNIT PRICE 1.7400	Sale *	-5,000.0000	8,700.00	(.18)	8,699.82	
11/27	ZTE CORP SHS CUS NO 98878Q105 UNIT PRICE 5.3100	Sale	-428.0000	2,272.68	(.05)	2,272.63	
12/05	SIENNA BIOPHARMACEUTICALS INC R VSP 11/25/19 13176 \$.171 CUS NO 82622H108 UNIT PRICE .2100	Sale	-13,176.0000	2,766.96	(.06)	2,766.90	
12/09	YIELD10 BIOSCIENCE INC CUS NO 98585K201 UNIT PRICE .1370	Sale	-6,486.0000	888.82	(.02)	888.80	
12/12	ALIBABA GROUP HOLDING LT CUS NO 01609W102 UNIT PRICE 201.9400	Sale	-1.0000	201.94	(.01)	201.93	
12/13	BELLICUM PHARMACEUTICALS ORD VSP 11/18/19 3342 \$.85 CUS NO 079481107 UNIT PRICE .8426	Sale	-3,342.0000	2,816.16	(.06)	2,816.10	
12/16	SIENNA BIOPHARMACEUTICALS INC R CUS NO 82622H108 UNIT PRICE .0705	Sale	-19,565.0000	1,381.23	(.03)	1,381.20	
12/30	ONCONOVA THERAPEUTICS INC CUS NO 68232V405 UNIT PRICE .3202	Sale	-5,181.0000	1,658.98	(.03)	1,658.95	
	<b>Subtotal (Sales)</b>			169,953.23	(100.67)	169,852.56	
<b>Other Security Transactions</b>							
12/12	TRANSENTERIX INC REG SHS PAY DATE 12/12/2019	Exchange	459.0000				
12/12	TRANSENTERIX INC PAY DATE 12/12/2019	Exchange	-5,963.0000				
12/13	TRANSENTERIX INC REG SHS PAY DATE 12/13/2019	Exchange	47.0000				
12/13	TRANSENTERIX INC	Exchange	-600.0000				

+

021

14 of 23

**Fill in this information to identify the case:**

Debtor 1 Lin Luo

Debtor 2 \_\_\_\_\_  
(Spouse, if filing)

United States Bankruptcy Court for the: District of Delaware

Case number 19-12748-LSS

**Official Form 410****Proof of Claim**

04/19

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

**Part 1: Identify the Claim**

1. Who is the current creditor?	<u>Lin Luo</u> Name of the current creditor (the person or entity to be paid for this claim)	
	Other names the creditor used with the debtor _____	
2. Has this claim been acquired from someone else?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. From whom? _____	
3. Where should notices and payments to the creditor be sent?  Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	<b>Where should notices to the creditor be sent?</b>  <u>Lin Luo</u> Name <u>11510 Bucknell Drive Apt 204</u> Number Street <u>Silver Spring</u> <u>MD</u> <u>20902</u> City State ZIP Code Contact phone <u>240-676-5824</u> Contact email <u>lnnluo@hotmail.com</u>	<b>Where should payments to the creditor be sent? (if different)</b>  Name _____ Number Street _____ City State ZIP Code _____ Contact phone _____ Contact email _____
Uniform claim identifier for electronic payments in chapter 13 (if you use one): _____		
4. Does this claim amend one already filed?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Claim number on court claims registry (if known) _____	
	Filed on _____ MM / DD / YYYY	
5. Do you know if anyone else has filed a proof of claim for this claim?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Who made the earlier filing? _____	

**Fill in this information to identify the case:**

Debtor 1 Lin Luo

Debtor 2 \_\_\_\_\_  
(Spouse, if filing)

United States Bankruptcy Court for the: District of Delaware

Case number 19-12748-LSS

**Official Form 410****Proof of Claim**

04/19

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies of any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. Do not send original documents; they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

**Part 1: Identify the Claim**

1. Who is the current creditor?	<u>Lin Luo</u> Name of the current creditor (the person or entity to be paid for this claim)  Other names the creditor used with the debtor _____	
2. Has this claim been acquired from someone else?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. From whom? _____	
3. Where should notices and payments to the creditor be sent?  Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	<b>Where should notices to the creditor be sent?</b>  <u>Lin Luo</u> Name <u>11510 Bucknell Drive Apt 204</u> Number Street <u>Silver Spring</u> <u>MD</u> <u>20902</u> City State ZIP Code Contact phone <u>240-676-5824</u> Contact email <u>lnnluo@hotmail.com</u>  Uniform claim identifier for electronic payments in chapter 13 (if you use one): _____	<b>Where should payments to the creditor be sent? (if different)</b>  _____ Name _____ Number Street _____ City State ZIP Code Contact phone _____ Contact email _____
4. Does this claim amend one already filed?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Claim number on court claims registry (if known) _____ Filed on ____ / ____ / ____	
5. Do you know if anyone else has filed a proof of claim for this claim?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Who made the earlier filing? _____	



**Part 2: Give Information About the Claim as of the Date the Case Was Filed**

6. Do you have any number you use to identify the debtor? ☐ No  
☒ Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor: 8 N 6 9

7. How much is the claim? \$ 3,022.28 Does this amount include interest or other charges?  
☒ No  
☐ Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).

8. What is the basis of the claim? Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card.  
 Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c).  
 Limit disclosing information that is entitled to privacy, such as health care information.  
567 quantity stock share of MLNT @ ave purchase prices of 3.95

9. Is all or part of the claim secured? ☒ No  
☐ Yes. The claim is secured by a lien on property.

**Nature of property:**  
☐ Real estate. If the claim is secured by the debtor's principal residence, file a *Mortgage Proof of Claim Attachment* (Official Form 410-A) with this *Proof of Claim*.  
☐ Motor vehicle  
☐ Other. Describe: \_\_\_\_\_

**Basis for perfection:** \_\_\_\_\_  
 Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)

**Value of property:** \$ \_\_\_\_\_  
**Amount of the claim that is secured:** \$ \_\_\_\_\_  
**Amount of the claim that is unsecured:** \$ \_\_\_\_\_ (The sum of the secured and unsecured amounts should match the amount in line 7.)

**Amount necessary to cure any default as of the date of the petition:** \$ \_\_\_\_\_

**Annual Interest Rate** (when case was filed) \_\_\_\_\_ %  
☐ Fixed  
☐ Variable

10. Is this claim based on a lease? ☒ No  
☐ Yes. Amount necessary to cure any default as of the date of the petition. \$ \_\_\_\_\_

11. Is this claim subject to a right of setoff? ☒ No  
☐ Yes. Identify the property: \_\_\_\_\_

**12. Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?**

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

- ☒ No  
☐ Yes. Check one:

- ☐ Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).  
☐ Up to \$3,025\* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).  
☐ Wages, salaries, or commissions (up to \$13,650\*) earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier. 11 U.S.C. § 507(a)(4).  
☐ Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).  
☐ Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).  
☐ Other. Specify subsection of 11 U.S.C. § 507(a)( ) that applies.

Amount entitled to priority

\$ \_\_\_\_\_

\$ \_\_\_\_\_

\$ \_\_\_\_\_

\$ \_\_\_\_\_

\$ \_\_\_\_\_

\$ \_\_\_\_\_

\* Amounts are subject to adjustment on 4/01/22 and every 3 years after that for cases begun on or after the date of adjustment.

**Part 3: Sign Below**

**The person completing this proof of claim must sign and date it. FRBP 9011(b).**

If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is.

**A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.**

Check the appropriate box:

- ☒ I am the creditor.  
☐ I am the creditor's attorney or authorized agent.  
☐ I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.  
☐ I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.

I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgment that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on date 02/12/2020  
MM / DD / YYYY

  
Signature

**Print the name of the person who is completing and signing this claim:**

Name Lin Luo  
First name Middle name Last name

Title \_\_\_\_\_

Company \_\_\_\_\_

Identify the corporate servicer as the company if the authorized agent is a servicer.

Address 11510 Bucknell Drive Apt 204  
Number Street

Silver Spring MD 20902  
City State ZIP Code

Contact phone 240-676-5824 Email Innluo@hotmail.com

February 12, 2020

Dear Madam or Sir,

My name is Lin Luo, born in 1976. My Bank of America Merill Edge account# is CMA-Edge [REDACTED] 8N69.

I own 567 share of common stocks of Melinta Therapeutics Inc.as of December 26, 2019 and as of today, with average unit cost of \$5.33 and total cost of \$3,022.28.

Sincerely,

A handwritten signature in black ink, consisting of stylized, cursive letters that appear to be 'LL' followed by a flourish.

Lin Luo

11510 Bucknell Drive Apt. 204

Silver Spring MD 20902

Email: [lnnluo@hotmail.com](mailto:lnnluo@hotmail.com) Phone# 240-676-5824





LIN LUO

Account Number: [REDACTED] 3N69

## YOUR CMA ASSETS

November 30, 2019 - December 31, 2019

CASH/MONEY ACCOUNTS	Quantity	Total Cost Basis	Estimated Market Price	Estimated Market Value	Estimated Annual Income	Est. Annual Yield%
CASH	0.25	0.25		.25		
+ML DIRECT DEPOSIT PROGRAM	29.00	29.00	1.0000	29.00		.05
+FDIC INSURED NOT SIPC COVERED						
TOTAL		29.25		29.25		.03

EQUITIES	Symbol	Acquired	Quantity	Unit Cost Basis	Total Cost Basis	Estimated Market Price	Estimated Market Value	Unrealized Gain/(Loss)	Estimated Annual Income
MELINTA THERAPEUTICS INC	MLNT	10/23/19	196.0000	4.4600	874.17	0.5311	104.10	(770.07)	
		10/23/19	371.0000	5.7900	2,148.11	0.5311	197.04	(1,951.07)	
Subtotal			567.0000		3,022.28		301.14	(2,721.14)	
TOTAL					3,022.28		301.14	(2,721.14)	

## LONG PORTFOLIO

Adjusted/Total Cost Basis	Estimated Market Value	Unrealized Gain/(Loss)	Estimated Accrued Interest	Estimated Annual Income
3,051.53	330.39	(2,721.14)		
TOTAL				

## Notes

♦Cost basis has been adjusted by the deferred loss amount from a previous "Wash Sale" and the acquisition date has been adjusted to include the holding period of the lot closed by that previous "Wash Sale".

## YOUR CMA TRANSACTIONS

DIVIDENDS/INTEREST INCOME TRANSACTIONS	Date	Description	Transaction Type	Quantity	Income	Year To Date
Taxable Interest						
Subtotal (Taxable Interest)						.11
NET TOTAL						.11

+

021

3 of 7

For best printing results, change page orientation to landscape.

Account Holdings for CMA-Edge 8N69

CMA-Edge 8N69

\$187.93

-\$27.78 -12.89%

Dow 29,379.77 +88.92 +0.30% NASDAQ 9,572.15 +63.47 +0.67% S&P 500 3,345.78 +11.09 +0.33% 10 Year T-Note 1.64 -0.00 -0.12% Real-time quotes

Group by ☒ Account ☐ Product Class

As of 02/06/2020 07:31 PM ET

Cash available to invest  
\$0.25

Settled cash buying power  
\$0.25

Unsettled cash  
\$0.00

Cash available to withdraw  
\$0.25

CMA-Edge 8N69

Value  
\$187.93

Day's Value Change  
-\$27.78 -12.89%

Un  
-\$2,83

Select view ☒ lin

Customize view

Symbol	Description	Price	Unit Cost	Quantity	Cost Basis	\$ Chg	Day's Price % Chg	Value	Day's Value Change \$	Un
MLNTQ	MELINTA THERAPEUTICS INC	\$0.3310	\$5.33	567	\$3,022.28	-\$0.0490	-12.90%	\$187.68	-\$27.78	-\$2,83
<b>Balances</b>										
Cash balance								\$0.25		
Pending activity								\$0.00		
<b>Total</b>								<b>\$187.93</b>	<b>-\$27.78</b>	<b>-\$2,83</b>

## Holdings by Product Class Report

The data displayed is for informational purposes only. Your account statement is the official record of your holdings and balances.

Review a description of the third-party ratings methodology.

Please note: None of Bank of America, Merrill Lynch or any affiliates, bears any responsibility or liability with respect to third-party research made available. Clients should understand that they assume full responsibility for any trading decisions they make based upon third-party ratings or reports.

Real-time market data on this page are for informational purposes only. The accuracy of this data is not warranted.

Quotes provided by Nasdaq Basic.

Information will not appear if a cost basis is not known, a security price is not currently available, or the Gain/(Loss) calculations are not appropriate for the type of holding.

Positions are net and cost basis excludes fractional shares.

Total unit cost represents weighted average acquisition price. It does not imply that any shares were actually purchased at that price.

Quotes provided by Nasdaq Basic.

[FAQs](#) | [Glossary](#) | [Contact Us](#) | [Privacy & Security](#) | [Careers](#) | [Advertising Practices](#)
[Site Map](#) | [Mobile Site](#) | [Forms & Applications](#) | [Web Accessibility](#) | [Fees \(PDF\)](#) | [ATM Locator](#) | [Legal Information](#) | [Routing & Executions](#) | [Software Requirements](#) | [Financial Information](#) | [Deposit Account & Money Fund Rates \(PDF\)](#) | [Co-Browse](#)

System availability and response time are subject to market conditions and possible unscheduled outages.

Market data provided by FactSet unless otherwise specified.

**Investing involves risks. There is always the potential of losing money when you invest in securities.**

Bank of America, Merrill, their affiliates, and advisors do not provide legal, tax, or accounting advice. Clients should consult their legal and/or tax advisors before making any financial decisions.

Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated (also referred to as "MLPF&amp;S" or "Merrill") makes available certain investment products sponsored, managed, distributed or provided by companies that are affiliates of Bank of America Corporation ("BoFA Corp.").

Merrill Lynch Life Agency Inc. (MLLA) is a licensed insurance agency and wholly owned subsidiary of BoFA Corp.

Bank of America, N.A, U.S Trust Company of Delaware, MLLA and MLPF&amp;S, a registered broker-dealer and Member Securities Investor Protection Corporation (SIPC), are wholly owned subsidiaries of BoFA Corp.

Trust and fiduciary services are provided by Bank of America, N.A., Member FDIC, or U.S. Trust Company of Delaware. Both are wholly owned subsidiaries of BoFA Corp.

Banking products are provided by Bank of America, N.A. and affiliated banks, Members FDIC and wholly owned subsidiaries of BoFA Corp.

**Investment products offered through MLPF&S and insurance and annuity products offered through MLLA:**

Are Not FDIC Insured	Are Not Bank Guaranteed	May Lose Value
Are Not Deposits	Are Not Insured by Any Federal Government Agency	Are Not a Condition to Any Banking Service or Activity

Online at: [www.merrilledge.com](http://www.merrilledge.com)

Account Number: [REDACTED] 3N69

24-Hour Assistance: (877) 653-4732  
Access Code: 22-549-78669LIN LUO  
11510 BUCKNELL DR APT 204  
SILVER SPRING MD 20902-2801

Net Portfolio Value: \$330.39

Your Merrill Office:  
Merrill EDGE  
FL9-802-03-05  
P.O. BOX 40486  
JACKSONVILLE, FL 32203

## CMA® ACCOUNT

This account is enrolled in the Preferred Rewards Platinum tier

November 30, 2019 - December 31, 2019

	This Statement	Year to Date
<b>Opening Value (11/30)</b>	<b>\$3,329.27</b>	
Total Credits	980.00	23,470.11
Total Debits	(3,750.00)	(18,267.00)
Securities You Transferred In/Out	-	-
Market Gains/(Losses)	(228.88)	(4,872.72)
<b>Closing Value (12/31)</b>	<b>\$330.39</b>	

### ASSETS

	December 31	November 29
Cash/Money Accounts	29.25	1.40
Fixed Income	-	-
Equities	301.14	3,327.87
Mutual Funds	-	-
Options	-	-
Other	-	-
Subtotal (Long Portfolio)	330.39	3,329.27
<b>TOTAL ASSETS</b>	<b>\$330.39</b>	<b>\$3,329.27</b>

### LIABILITIES

Debit Balance	-	-
Short Market Value	-	-
<b>TOTAL LIABILITIES</b>	<b>-</b>	<b>-</b>
<b>NET PORTFOLIO VALUE</b>	<b>\$330.39</b>	<b>\$3,329.27</b>

Merrill Lynch, Pierce, Fenner & Smith Incorporated (also referred to as "MLPF&S" or "Merrill") makes available certain investment products sponsored, managed, distributed or provided by companies that are affiliates of Bank of America Corporation (BofA Corp). MLPF&S is a registered broker-dealer, Member SIPC and a wholly owned subsidiary of BofA Corp. Investment products: ☐ Are Not FDIC Insured ☐ Are Not Bank Guaranteed ☐ May Lose Value



**Part 2: Give Information About the Claim as of the Date the Case Was Filed**

6.	Do you have any number you use to identify the debtor?	<input type="checkbox"/> No <input checked="" type="checkbox"/> Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor:	<u>8</u> <u>K</u> <u>9</u> <u>3</u>
7.	How much is the claim?	\$ <u>3,283.98</u>	Does this amount include interest or other charges? <input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).
8.	What is the basis of the claim?	Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card. Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c). Limit disclosing information that is entitled to privacy, such as health care information.  <u>2,234 quantity stock share of MLNT @ ave purchase prices of 3.95</u>	
9.	Is all or part of the claim secured?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. The claim is secured by a lien on property.  <b>Nature of property:</b> <input type="checkbox"/> Real estate. If the claim is secured by the debtor's principal residence, file a <i>Mortgage Proof of Claim Attachment</i> (Official Form 410-A) with this <i>Proof of Claim</i> . <input type="checkbox"/> Motor vehicle <input type="checkbox"/> Other. Describe: _____  <b>Basis for perfection:</b> _____ Attach redacted copies of documents, if any, that show evidence of perfection of a security interest (for example, a mortgage, lien, certificate of title, financing statement, or other document that shows the lien has been filed or recorded.)  <b>Value of property:</b> \$ _____ <b>Amount of the claim that is secured:</b> \$ _____ <b>Amount of the claim that is unsecured:</b> \$ _____ (The sum of the secured and unsecured amounts should match the amount in line 7.)  <b>Amount necessary to cure any default as of the date of the petition:</b> \$ _____  <b>Annual Interest Rate</b> (when case was filed) _____ % <input type="checkbox"/> Fixed <input type="checkbox"/> Variable	
10.	Is this claim based on a lease?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Amount necessary to cure any default as of the date of the petition. \$ _____	
11.	Is this claim subject to a right of setoff?	<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes. Identify the property: _____	

Online at: [www.merrilledge.com](http://www.merrilledge.com)

Account Number: [REDACTED] 3K93

24-Hour Assistance: (877) 653-4732

Access Code: 22-209-78593

MLPF&amp;S CUST FPO

LIN LUO RRA

FBO LIN LUO

11510 BUCKNELL DR APT 204

SILVER SPRING MD 20902-2801

Net Portfolio Value: \$1,211.59

Your Merrill Office:

Merrill EDGE

FL9-802-03-05

P.O. BOX 40486

JACKSONVILLE, FL 32203

This account is enrolled in the Preferred Rewards Platinum tier

October 01, 2019 - December 31, 2019

## RETIREMENT ACCOUNT

	This Statement	Year to Date
<b>Opening Value (10/01)</b>	\$1,209.01	
Total Credits	0.07	1,558.08
Total Debits	-	-
Securities You Transferred In/Out	-	-
Market Gains/(Losses)	2.51	(346.49) *
<b>Closing Value (12/31)</b>	\$1,211.59	

### ASSETS

Cash/Money Accounts	December 31	September 30
Fixed Income	0.71	1.76
Equities	-	-
Mutual Funds	1,210.88	1,207.25
Options	-	-
Other/Annuities/Insurance	-	-
Subtotal (Long Portfolio)	1,211.59	1,209.01
<b>TOTAL ASSETS</b>	<b>\$1,211.59</b>	<b>\$1,209.01</b>

### LIABILITIES

Debit Balance	December 31	September 30
TOTAL LIABILITIES	-	-
<b>NET PORTFOLIO VALUE</b>	<b>\$1,211.59</b>	<b>\$1,209.01</b>

Merrill Lynch, Pierce, Fenner & Smith Incorporated (also referred to as "MLPF&S" or "Merrill") makes available certain investment products sponsored, managed, distributed or provided by companies that are affiliates of Bank of America Corporation (BofA Corp). MLPF&S is a registered broker-dealer, Member SIPC and a wholly owned subsidiary of BofA Corp. Investment products: ☐ Are Not FDIC Insured ☐ Are Not Bank Guaranteed ☐ May Lose Value

+

For best printing results, change page orientation to landscape.

## Account Holdings for

Roth IRA-Edge [REDACTED] 8K93

Roth IRA-Edge [REDACTED] 8K93

\$761.36

-\$110.77 -12.71%

Dow 29,379.77 +88.92 +0.30%

NASDAQ 9,572.15 +63.47 +0.67%

+0.67%

S&amp;P 500 3,345.78 +11.09 +0.33%

+0.33%

10 Year T-Note 1.64 -0.00

-0.12%

Real-time quotes

Group by ☒ Account ☐ Product Class

As of 02/06/2020 07:29 PM ET

Cash available to invest  
\$0.71Settled cash buying power  
\$0.71Unsettled cash  
\$0.00

Roth IRA-Edge [REDACTED] 8K93

Value  
\$761.36Day's Value Change  
-\$110.77 -12.71%Un  
-\$2,54Select view 

Symbol	Description	Price	Unit Cost	Quantity	Cost Basis	\$ Chg	Day's Price % Chg	Value	Day's Value Change \$	Un
MLNTQ	MELINTA THERAPEUTICS INC	\$0.3310	\$1.47	2,234 *	\$3,283.98 *	-\$0.0490	-12.90%	\$739.45	-\$109.47	-\$2,54
RMTI	ROCKWELL MEDICAL TECH	\$2.12	\$2.02	10	\$20.20	-\$0.13	-5.78%	\$21.20	-\$1.30	+\$
<b>Balances</b>										
Cash balance								\$0.71		
Pending activity								\$0.00		
<b>Total</b>								<b>\$761.36</b>	<b>-\$110.77</b>	<b>-\$2,54</b>

## Holdings by Product Class Report

The data displayed is for informational purposes only. Your account statement is the official record of your holdings and balances.

Review a description of the third-party ratings methodology.

Please note: None of Bank of America, Merrill Lynch or any affiliates, bears any responsibility or liability with respect to third-party research made available. Clients should understand that they assume full responsibility for any trading decisions they make based upon third-party ratings or reports.

Real-time market data on this page are for informational purposes only. The accuracy of this data is not warranted.

Quotes provided by Nasdaq Basic.

Information will not appear if a cost basis is not known, a security price is not currently available, or the Gain/(Loss) calculations are not appropriate for the type of holding.

Positions are net and cost basis excludes fractional shares.

Total unit cost represents weighted average acquisition price. It does not imply that any shares were actually purchased at that price.

Quotes provided by Nasdaq Basic.

[FAQs](#) | [Glossary](#) | [Contact Us](#) | [Privacy & Security](#) | [Careers](#) | [Advertising Practices](#)
[Site Map](#) | [Mobile Site](#) | [Forms & Applications](#) | [Web Accessibility](#) | [Fees \(PDF\)](#) | [ATM Locator](#) | [Legal Information](#) | [Routing & Executions](#) | [Software Requirements](#) | [Financial Information](#) | [Deposit Account & Money Fund Rates \(PCF\)](#) | [Co-Browse](#)

System availability and response time are subject to market conditions and possible unscheduled outages.

Market data provided by FactSet unless otherwise specified.

**Investing involves risks. There is always the potential of losing money when you invest in securities.**

Bank of America, Merrill, their affiliates, and advisors do not provide legal, tax, or accounting advice. Clients should consult their legal and/or tax advisors before making any financial decisions.

Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated (also referred to as "MLPF&amp;S" or "Merrill") makes available certain investment products sponsored, managed, distributed or provided by companies that are affiliates of Bank of America Corporation ("BoFA Corp.").

Merrill Lynch Life Agency Inc. (MLLA) is a licensed insurance agency and wholly owned subsidiary of BoFA Corp.

Bank of America, N.A. U.S. Trust Company of Delaware, MLLA and MLPF&amp;S, a registered broker-dealer and Member Securities Investor Protection Corporation (SIPC), are wholly owned subsidiaries of BoFA Corp.

Trust and fiduciary services are provided by Bank of America, N.A., Member FDIC, or U.S. Trust Company of Delaware. Both are wholly owned subsidiaries of BoFA Corp.

Banking products are provided by Bank of America, N.A. and affiliated banks, Members FDIC and wholly owned subsidiaries of BoFA Corp.

**Investment products offered through MLPF&S and insurance and annuity products offered through MLLA:**

Are Not FDIC Insured	Are Not Bank Guaranteed	May Lose Value
----------------------	-------------------------	----------------





FBO LIN LUO

Account Number: [REDACTED] 8K93

## YOUR RETIREMENT ACCOUNT ASSETS

October 01, 2019 - December 31, 2019

CASH/MONEY ACCOUNTS Description	Quantity	Total Cost Basis	Estimated Market Price	Estimated Market Value	Estimated Market Value	Estimated Market Price	Total Cost Basis	Unit Cost Basis	Quantity	Estimated Market Price	Estimated Market Value	Estimated Market Value	Estimated Annual Income	Est. Annual Yield%
CASH	0.71	0.71									.71			
EQUITIES														
Description	Symbol	Acquired	Quantity	Cost Basis	Unit	Estimated Market Price	Total Cost Basis	Estimated Market Price	Estimated Market Value	Estimated Market Value	Estimated Annual Income	Unrealized Gain/(Loss)	Estimated Annual Income	Estimated Annual Income
MELINTA THERAPEUTICS INC	MLNT	12/26/19 *	2,234.0000	1.4700		0.5311	3,283.98		1,186.48		(2,097.50)			
ROCKWELL MEDICAL TECH	RMTI	11/04/19	10.0000	2.0200		2.4400	20.20		24.40		4.20			
TOTAL							3,304.18		1,210.88		(2,093.30)			

## LONG PORTFOLIO

Description	Adjusted/Total Cost Basis	Estimated Market/ Contract Value	Unrealized Gain/(Loss)	Estimated Accrued Interest	Estimated Annual Income
TOTAL	3,304.89	1,211.59	(2,093.30)		

## YOUR RETIREMENT ACCOUNT TRANSACTIONS

DIVIDENDS/INTEREST INCOME TRANSACTIONS		Transaction Type	Quantity	Income	Income Year To Date
Date	Description				
11/05	BANK OF AMERICA, NA RASP PAY DATE 11/04/2019 FROM 10-31 THRU 11-04 CUSIP NUM: 55499U915	Interest		.01	
12/31	BANK OF AMERICA, NA RASP PAY DATE 12/30/2019 FROM 11-29 THRU 12-30 CUSIP NUM: 55499U915	Interest		.06	
Subtotal (Tax-Exempt Interest)				.07	.08
NET TOTAL				.07	.08

## SECURITY TRANSACTIONS

Settlement Date	Description	Transaction Type	Quantity	Transaction Amount	Commissions/ Trading Fees	(Debit)/ Credit	Accrued Interest Earned/(Paid)
10/01	MEDMEN ENTERPRISES INC	Purchase	852.0000	(1,286.52)	(6.95)	(1,293.47)	

+

February 12, 2020

Dear Madam or Sir,

My name is Lin Luo, born in 1976. My Bank of America Merrill Edge account# is Roth IRA-Edge [REDACTED] 3K93.

I own 2,234 share of common stocks of Melinta Therapeutics Inc. as of December 26, 2019 and as of today, with average unit cost of \$1.47 and total cost of \$3,283.98.

Sincerely,

A handwritten signature in black ink, appearing to be 'LL' with a long horizontal stroke extending to the right.

Lin Luo

11510 Bucknell Drive Apt. 204

Silver Spring MD 20902

Email: [lnnluo@hotmail.com](mailto:lnnluo@hotmail.com) Phone# 240-676-5824

**12. Is all or part of the claim entitled to priority under 11 U.S.C. § 507(a)?**☒ No☐ Yes. Check one:

A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount entitled to priority.

☐ Domestic support obligations (including alimony and child support) under 11 U.S.C. § 507(a)(1)(A) or (a)(1)(B).

Amount entitled to priority

\$ \_\_\_\_\_

☐ Up to \$3,025\* of deposits toward purchase, lease, or rental of property or services for personal, family, or household use. 11 U.S.C. § 507(a)(7).

\$ \_\_\_\_\_

☐ Wages, salaries, or commissions (up to \$13,650\*) earned within 180 days before the bankruptcy petition is filed or the debtor's business ends, whichever is earlier. 11 U.S.C. § 507(a)(4).

\$ \_\_\_\_\_

☐ Taxes or penalties owed to governmental units. 11 U.S.C. § 507(a)(8).

\$ \_\_\_\_\_

☐ Contributions to an employee benefit plan. 11 U.S.C. § 507(a)(5).

\$ \_\_\_\_\_

☐ Other. Specify subsection of 11 U.S.C. § 507(a)( ) that applies.

\$ \_\_\_\_\_

\* Amounts are subject to adjustment on 4/01/22 and every 3 years after that for cases begun on or after the date of adjustment.

**Part 3: Sign Below**

The person completing this proof of claim must sign and date it. FRBP 9011(b).

If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Check the appropriate box:


☒ I am the creditor.☐ I am the creditor's attorney or authorized agent.☐ I am the trustee, or the debtor, or their authorized agent. Bankruptcy Rule 3004.☐ I am a guarantor, surety, endorser, or other codebtor. Bankruptcy Rule 3005.

I understand that an authorized signature on this *Proof of Claim* serves as an acknowledgment that when calculating the amount of the claim, the creditor gave the debtor credit for any payments received toward the debt.

I have examined the information in this *Proof of Claim* and have a reasonable belief that the information is true and correct.

I declare under penalty of perjury that the foregoing is true and correct.

Executed on date 02/12/2020  
MM / DD / YYYY



Signature

**Print the name of the person who is completing and signing this claim:**

Name Lin Luo  
First name Middle name Last name

Title \_\_\_\_\_

Company \_\_\_\_\_  
Identify the corporate servicer as the company if the authorized agent is a servicer.

Address 11510 Bucknell Drive Apt 204  
Number Street  
Silver Spring MD 20902  
City State ZIP Code

Contact phone 240-676-5824 Email Innluo@hotmail.com